tbuckley/cabot-search huggingface dataset:
Abstract 14094: Tuberculous Effusive-Constrictive Pericarditis: Prevalence, Predictors and Prognosis
Authors: Bongani M Mayosi, Mpiko Ntsekhe, Kerryn Matthews, Armin Deffur, Faisal F Syed, Motasim Badri, Bernard J Gersh, Patrick J Commerford, Katalin A Wilkinson, Robert J Wilkinson
Journal: Circulation (2012)

Introduction Effusive-constrictive pericarditis (ECP) is characterized by visceral pericardial constriction in conjunction with compressive pericardial effusion and considered to be an indication f...
Abstract 13158: Lipoprotein-Associated Phospholipase A2 is Associated with Cardiovascular Mortality and Subclinical Atherosclerosis Phenotypes in African-Americans
Authors: Andres deLuna, Emmanouil Brilakis, Colby Ayers, Darren McGuire, James deLemos, Amit Khera
Journal: Circulation (2012)

Introduction Lipoprotein-associated Phospholipase A2 (Lp-PLA2) is an enzyme that has been implicated to have a pro-atherogenic role in multiple studies, however, these studies predominantly include...
Breast cancer staging and treatment planning according to internal mammary lymph node status
Authors: A. Petrovsky, A. Trigolosov, Y. Vishnevskaya, B. Polyakov, S. Tjulandin, M. Nechushkin
Journal: Journal of Clinical Oncology (2005)

718 Background: According to different authors the rate of the internal mammary lymph nodes (IMN) metastasis in breast cancer patients is in the range from 12 to 55%. Unfortunately nowadays there is the lack of the preoperative non-invasive routine techniques for the definite detection of the IMN involvement. Methods: During 1998–2004 1269 patients underwent either video-thoracoscopic IMN dissection (VIMND) (828women) or open IMN biopsy (OIMNB) through I-III intercostal space (441 women) during regular mastectomy or radical resection of the breast. Only patients with verified INM metastasis underwent radiation therapy (RT) at this zone. RT at the breast and axilla was performed according to regular indications. All the patients received chemotherapy and hormonal therapy if necessary. Results: 249 of all the patients (19.6%) had morphologically verified metastasis in IMN. In 5.2% IMN involvement was detected without axilllary lymph node metastasis. Very low rate (2.3%) of intra and post-surgical complications connected to VIMND could be registered in all the patients. No specific complications were detected during or after OIMNB.According to our results there is IMN spread dependence on the size,location and histological structure of primary breast tumor, the additional involvement of the axilllary lymph nodes and patients age, and no statistically significant relationship could be found with estrogen receptor level and menstruation function of the patients. No reccurence in parasternal region was detected in non-radiated women in 6-year monitoring period. Conclusions: Both techniques could be recommended to the breast cancer patients for correct staging. Only patients with verified metastasis at IMN should receive radiation therapy at this zone. No significant financial relationships to disclose.
Improving immunization (imm) rates among oncology patients and health care providers (HCP) through a partnership of continuing medical education (CME) and quality improvement (QI) in an NCI-designated comprehensive cancer center.
Authors: Lucille A. Leong, Mary Mendelsohn, Ted Bruno, Jean Kagan, Crystal J. Saavedra, Wendy Scales, Robert Morgan
Journal: Journal of Clinical Oncology (2013)

43 Background: Onc pts are at increased risk of vaccine (vac)-preventable diseases and suffer worse sequelae. Regulatory requirements demand imm of patients and HCP. There is a large practice gap among clinicians in awareness of imm guidelines, of pt imm status, and of the high risk of transmission from HCP to immunocompromised pt. Methods: From May 2012 to June 2013 the City of Hope CME coordinated a team of MDs, QI specialists, infection control, IT, nursing, and pharmacy in a QI CME initiative to increase the imm rates of pt and HCP by education (ed) to clinicians, pt and families. Multiple ed platforms were used (live CME meetings, web-based content, point of care applications, visual cues, clinician longitudinal self-assessment surveys, systems-based support tools, patient handouts) with emphasis on MD-friendly platforms. Results: &gt;350 HCP participated in CME events (59% MDs, 18% RN). Analysis of ed and clinical outcomes is from 4 areas. (1) Change in HCP attitudes through self-assessment surveys shows an increase in clinician knowledge of types and timing of imm, in use of system-based tools (standard orders, vac computerized manager), and in involvement of pts in imm history and ed. (2) There was an increase of doses of influenza vaccines in pts (Sept-March, 2010-11/ 2011-12/ 2012-13: 1129/1480(31% increase)/1838(24% increase). (3) Respiratory viral testing of pts was done to assess number of confirmed infections. (4) Influenza vac rates of hospital workers improved with the largest increase in the medical staff (65 to 76%). Conclusions: This interdisciplinary CME initiative to improve imm rates among onc pts involved ed activities and system-based changes. Improvements were seen in areas of HCP attitude, performance, and acceptance of their own vac. 24% of the medical staff remain unvaccinated, raising both ethical and compliance challenges to reach the 2020 90% goal of Joint Commission. A gap remains in HCP attitudes regarding their own vac which may not be amenable to analytical-based CME. Use of other decision-making/learning styles is necessary for further progress. CA62505 and Pfizer.
The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative
Authors: Efstathios Zikos, Corneel Coens, Chantal Quinten, Divine E. Ediebah, Francesca Martinelli, Irina Ghislain, Madeleine T. King, Carolyn Gotay, Jolie Ringash, Galina Velikova, Bryce B. Reeve, Eva Greimel, Charles S. Cleeland, Henning Flechtner, Martin J. B. Taphoorn, Joachim Weis, Joseph Schmucker-von Koch, Mirjam A. G. Sprangers, Andrew Bottomley
Journal: JNCI Journal of the National Cancer Institute (2015)

The European Organisation for Research and Treatment of Cancer (EORTC) Patient-Reported Outcomes and Behavioural Evidence (PROBE) initiative was established to investigate critical topics to better understand health-related quality of life (HRQOL) of cancer patients and to educate clinicians, policy makers, and healthcare providers. The aim of this paper is to review the major research outcomes of the pooled analysis of HRQOL data along with the clinical data. We identified 30 pooled EORTC randomized controlled trials (RCTs), 18 NCIC-Clinical Trials Group RCTs, and two German Ovarian Cancer Study Group RCTs, all using the EORTC QLQ-C30. All statistical tests were two-sided. Evidence was found that HRQOL data can offer prognostic information beyond clinical measures and improve prognostic accuracy in cancer RCTs (by 5.9%-8.3%). Moreover, models that considered both patient- and clinician-reported scores gained more prognostic overall survival accuracy for fatigue ( P < .001), vomiting ( P = .01), nausea ( P < .001), and constipation ( P = .01). Greater understanding of the association between symptom and/or functioning scales was developed by identifying physical, psychological, and gastrointestinal clusters. Additionally, minimally important differences in interpreting HRQOL changes for improvement and deterioration were found to vary across different patient populations and disease stages. Finally, HRQOL scores are statistically significantly affected by deviations from the intended time point at which the questionnaire is completed. The use of existing pooled data shows that it is possible to learn about general aspects of cancer HRQOL and methodology. Our work shows that setting up international pooled datasets holds great promise for understanding patients' unmet psychosocial needs and calls for additional empirical investigation to improve clinical care and understand cancer through retrospective HRQOL analyses.
Imatinib pharmacokinetics (PK) and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST)
Authors: M. von Mehren, Y. Wang, H. Joensuu, C. D. Blanke, E. Wehrle, G. D. Demetri
Journal: Journal of Clinical Oncology (2008)

4523 Background: In the phase II study B2222, 147 pts with unresectable/metastatic GIST were randomized 1:1 to receive imatinib (IM) at 400 vs 600 mg daily. The estimated survival rate at 60 months was 47.6%. We report the PK of IM and the correlation of IM levels with clinical response. Methods: The IM plasma levels were analyzed in a subset of pts (n=73) for whom PK data on day 1 of treatment or at steady state (Day 29) was available (n=34 and 39 for 400 and 600 mg/day, respectively). IM PK was evaluated using a population PK approach. A correlation between IM plasma exposure and clinical outcome was explored by grouping pts into quartiles according to IM trough levels at steady state (Cmin). The clinical outcome parameters evaluated include overall objective responses (OOR=CR+PR), time to progression (TTP), and KIT mutation status. Results: Clinical response tended to correlate with IM trough exposure. OOR was achieved by 8 of 18 (44%) pts in Q1 (Cmin <1,110 ng/mL) compared with 24 of 36 (67%) and 14 of 19 (74%) in Q2-Q3 (≥1,110 - <2,040 ng/mL), and Q4 (≥2,040 ng/mL), respectively (p=0.060 for Q1 vs Q2-Q4). The median TTP was 11.3 months for pts in Q1 and over 30 months for Q2-Q4 (p=0.0029). In pts with GIST with exon 11 KIT mutation (n=39), the OOR was 55.6% for Q1 vs 93.3% for Q2-Q4 (p=0.006). The IM plasma AUC, peak concentration, and Cmin were highly correlated, with IM Cmin having the best correlation with response. Conclusions: Exposure to adequate drug levels of IM appears to correlate with clinical benefit; pts with the lowest IM levels show the lowest OOR and shortest TTP. These results suggest that monitoring IM exposure may be important for optimal clinical outcome. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Novartis Infinity, MedImmune, Novartis, Pfizer Novartis MedImmune, Novartis, Pfizer Infinity, Novartis, Pfizer Infinity, Novartis, Pfizer
Delays from symptom onset to treatment in malignant spinal cord compression: Quantification and effect on pre-treatment neurological status
Authors: G. Mitera, A. Loblaw
Journal: Journal of Clinical Oncology (2004)

8276 Background: Malignant spinal cord compression (MSCC) is a devastating complication of advanced malignancy. Any delay in initiation of radiation treatment may result in a deterioration of pre-treatment neurological function; hence, a poorer prognosis of post treatment outcome and quality of life. A British study documented significant delays in patients with MSCC, the majority losing neurological function as a result. The objective of this study was to prospectively document patterns of care from symptom onset of MSCC until initiation of radiation treatment at our centre, and investigate potential affects on pre-treatment neurological status. Methods: A standardized data collection form was used to document demographics, tumor and functional information; and centre and referring doctors' charts were used to augment patient history. Chi-squared analysis and Person's r correlation determined statistical significance. Thirty patients identified from Jan/03-Dec/03 were accrued. Three subgroups were formed based on time from symptom onset until RT treatment: 0–7 days, 8–14 days, and >14 days. Results: A median delay of 16 days from symptom onset till RT treatment was experienced, of which 90% resulted from symptom onset to initiation of medical attention. When patients perceived symptoms to be related to their previous cancer the median time delay was 6 days, compared to 7 days when patients related symptoms to other co-morbidities. Conclusions: Deterioration of symptoms was strongly correlated with time delay in patients with MSCC at our centre, thereby supporting prevention and educational strategies to help reduce the impact of this complication on patients with advanced cancer. No significant financial relationships to disclose.
Hamstring injuries have increased by 4% annually in men's professional football, since 2001: a 13-year longitudinal analysis of the UEFA Elite Club injury study
Authors: Jan Ekstrand, Markus Waldén, Martin Hägglund
Journal: British Journal of Sports Medicine (2016)

There are limited data on hamstring injury rates over time in football.To analyse time trends in hamstring injury rates in male professional footballers over 13 consecutive seasons and to distinguish the relative contribution of training and match injuries.36 clubs from 12 European countries were followed between 2001 and 2014. Team medical staff recorded individual player exposure and time-loss injuries. Injuries per 1000 h were compared as a rate ratio (RR) with 95% CI. Injury burden was the number of lay off days per 1000 h. Seasonal trend for injury was analysed using linear regression.A total of 1614 hamstring injuries were recorded; 22% of players sustained at least one hamstring injury during a season. The overall hamstring injury rate over the 13-year period was 1.20 injuries per 1000 h; the match injury rate (4.77) being 9 times higher than the training injury rate (0.51; RR 9.4; 95% CI 8.5 to 10.4). The time-trend analysis showed an annual average 2.3% year on year increase in the total hamstring injury rate over the 13-year period (R(2)=0.431, b=0.023, 95% CI 0.006 to 0.041, p=0.015). This increase over time was most pronounced for training injuries-these increased by 4.0% per year (R(2)=0.450, b=0.040, 95% CI 0.011 to 0.070, p=0.012). The average hamstring injury burden was 19.7 days per 1000 h (annual average increase 4.1%) (R(2)=0.437, b=0.041, 95% CI 0.010 to 0.072, p=0.014).Training-related hamstring injury rates have increased substantially since 2001 but match-related injury rates have remained stable. The challenge is for clubs to reduce training-related hamstring injury rates without impairing match performance.
Late cardiovascular toxicity of BEP regimen among testicular cancer patients
Authors: M. A. Sadowska, P. J. Wiechno, L. Greszata, B. Paluchowska, T. Demkow
Journal: Journal of Clinical Oncology (2006)

14658 Background: Testicular cancer is the most common neoplasm in young men population. Standard chemotherapy for metastatic disease is BEP regimen (cisplatin, bleomycin, etopozyd). Evaluation of some late toxicities regarding cardiovascular system in patients with testicular cancer treated with orchidectomy and standard BEP regimen in comparison with patients treated with orchidectomy alone is presented. Methods: From February 2003 till July 2004, 153 patients (median age 37 year, range: 19–70) were enrolled into the study. The first group consisted of 93 men with metastatic testicular cancer, treated with orchidectomy and standard BEP regimen (3–10 courses, median 4). A control group consisted of 60 patients with stage I testicular cancer, after orchidectomy but without cytotoxic treatment. The patients who failed first line treatment or progressed were excluded from the study. Disease free survival was at least 2 years, median - 74 months (range: 24–327). Authors of the study created an inventory assessing cardiovascular risk factors, which was completed by every patient. Evaluation of the patient consisted of ECG, echocardiography, blood tests, assessment of the Body Mass Index and the risk of cardiac ischaemia incident according to the Polish Society of Cardiology guidelines. Results: Abnormal cardiac rhythm was more frequent among patients after chemotherapy then without cytotoxic treatment (24,8% and 6,7%, retrospectively, p = 0.004). There was also statistically important association between abnormal cardiac rhythm and the number of courses administered (p = 0.008). There were no statistically significant differences in conduction abnormalities (p = 0.218), echocardiography abnormalities (p = 0.72) and dimensions of the heart cavities (p = 0.26). Risk of cardiac ischaemia incident was similar in BEP and control groups (low risk 7.5% vs. 3,3%, moderate 26.9% vs. 16,7%, high 33.3% vs. 45% and very high 24.7% vs. 25%). There were no statistically significant differences between the two groups regarding abnormal BMI or lipidogram. Abnormal blood magnesium levels were more frequent among patients after chemotherapy (p = 0.009). Conclusions: Chemotherapy with BEP regimen increases the risk of rhythm abnormalities and the rate of abnormal blood magnesium level. No significant financial relationships to disclose.
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
Authors: P. D. Ryan, N. M. Tung, S. J. Isakoff, M. Golshan, A. Richardson, A. D. Corben, B. L. Smith, R. Gelman, E. P. Winer, J. E. Garber
Journal: Journal of Clinical Oncology (2009)

551 Background: We have previously shown that neoadjuvant cisplatin has activity in TNBC, a subtype of breast cancer for which there is no effective targeted therapy. Bevacizumab adds to the efficacy of chemotherapy in metastatic breast cancer; however, there is limited data on the safety or efficacy of bevacizumab in combination with chemotherapy in the neoadjuvant or adjuvant setting. Thus, we sought to explore the safety and efficacy of the addition of bevacizumab to cisplatin in the treatment of TNBC. Methods: 51 patients (pts) with confirmed TNBC provided informed consent and were enrolled in a single arm phase II trial of neoadjuvant cisplatin 75 mg/m 2 q 3 weeks x 4 cycles and bevacizumab 15 mg/kg q 3 weeks x 3 cycles prior to definitive surgery. Only 3 cycles of bevacizumab were delivered to allow 6 weeks between the last dose of bevacizumab and surgery. Research biopsies were obtained and breast MRI performed before treatment and at surgery. Postoperatively, pts received doxorubicin and cytoxan (AC) plus bevacizumab or AC/Taxol plus bevacizumab. Median age was 50 yrs (range 30 to 66 yrs); tumors were clinical T1 (2%), T2 (80%), T3 (18%). Results: Forty-six pts are evaluable for response and 5 pts are still receiving neoadjuvant therapy. Clinical responses to date: 12/46 (26%) clinical complete response (cCR), 24/46 (52%) clinical partial response (cPR), 5/46 (11%) stable disease (SD), and 1/46 (2%) progressive disease (PD). Non-responders included 4/46 (9%) pts who discontinued protocol therapy for toxicity. To date, 7/46 (15%) pts achieved a complete pathological response (Miller-Payne 5) and an additional 10/46 (22%) were Miller-Payne 4. Five pts did not complete neoadjuvant therapy, 2 with tinnitus/hearing loss and 3 with grade 4 toxicities consisting of refractory hypertension in 1 pt and pulmonary embolism (PE) in 2 pts. Tissue-based assays to predict platinum/bevacizumab responses, including BRCA1/2 status, are underway. Conclusions: Cisplatin and bevacizumab has some activity in TNBC as demonstrated by 37% of evaluable pts with a Miller-Payne 4 or 5 pathological response. However, toxicity, including tinnitus/hearing loss, hypertension and PE, limited completion of neoadjuvant therapy in 11% of pts. No significant financial relationships to disclose.
Hematopoietic stem cell transplantation for HIV cure
Authors: Daniel R. Kuritzkes
Journal: Journal of Clinical Investigation (2016)

The apparent cure of an HIV-infected person following hematopoietic stem cell transplantation (HSCT) from an allogeneic donor homozygous for the ccr5Δ32 mutation has stimulated the search for strategies to eradicate HIV or to induce long-term remission without requiring ongoing antiretroviral therapy. A variety of approaches, including allogeneic HSCT from CCR5-deficient donors and autologous transplantation of genetically modified hematopoietic stem cells, are currently under investigation. This Review covers the experience with HSCT in HIV infection to date and provides a survey of ongoing work in the field. The challenges of developing HSCT for HIV cure in the context of safe, effective, and convenient once-daily antiretroviral therapy are also discussed.
Phase II study of gemcitabine single agent for patients with advanced nasopharyngeal carcinoma (NPC) who failed to first line platinum-based chemotherapy
Authors: L. Zhang, Z. Z. Guan, Y. Zhang
Journal: Journal of Clinical Oncology (2004)

5612 Background: This single arm phase II study was to evaluate efficacy and toxicity profile of gemcitabine single agent in previously treated NPC patients who failed to first line platinum based regimen. Methods: Patients with pathological or histological confirmed local advanced or metastatic NPC, presenting at least one measurable lesion and have failed to one platinum-containing regimen were eligible for this study. Gemcitabine 1000mg/m2 was administrated on days 1,8,15 of every 28-day cycle. WHO response rate criteria and CTC toxicity grading criteria were applied. Results: 23 patients were enrolled into the study and 20 of them were eligible. 57 cycles were administered with an average of 2.85 cycles per patient. Over all response rate (CR + PR) was observed in 11 patients (55.0%), while 5 patients with SD and 4 with PD (25% vs. 20%). Survival data has not been achieved yet. The major adverse events were hematologic toxicities, Grade III neutropenia was seen in 5 patients (25%), Grade III thrombocytopenia was seen in 1 patient (5%), non garde IV hematological toxicities was observed. All non-hematologic toxicities were mild and manageable. Conclusions: Gemcitabine single agent was effective and well-tolerated for NPC patients who failed to prior platinum based treatment.. No significant financial relationships to disclose.
Alcohol Intake and Colorectal Cancer
Authors: Eunyoung Cho, Stephanie A. Smith-Warner, John Ritz, Piet A. Van Den Brandt, Graham A. Colditz, Aaron R Folsom, Jo L. Freudenheim, Edward Giovannucci, R. Alexandra Goldbohm, Saxon Graham, Lars Holmberg, Dong Hyun Kim, Nea Malila, Anthony B. Miller, Pirjo Pietinen, Thomas E. Rohan, Thomas A. Sellers, Frank E. Speizer, Walter C. Willett, Alicja Wolk, David J. Hunter
Journal: Annals of Internal Medicine (2004)